Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

World Allergy Organization Journal

Carlos D Serrano¹  Eduardo Egea⁴  Elizabeth García⁵  Mario Sanchez Borges²  Diana C Carrillo³ 

[1] Allergy Unit, Fundacion Valle del Lili, Carrera 98 # 18-49, Cali, Colombia;Allergy and Clinical Immunology Department, Centro Médico-Docente La Trinidad, Avenida Intercomunal La Trinidad, El Hatillo, Apartado Postal 80474, Caracas, 1080-A, Venezuela;Department of Internal Medicine, Fundación Valle del Lili, Carrera 98 # 18-49, Cali, Colombia;Medicine Department. Universidad del Norte, Kilometro 5 vía a Puerto Colombia, Barranquilla, Colombia;Allergy Unit, Fundación Santa Fé de Bogotá, Carrera 7B # 123-90, Bogotá, Colombia

关键词: Angioedema;    Urticaria;    Humanized;    Monoclonal;    Antibodies;   

Others  :  1137524
DOI  :  10.1186/s40413-014-0050-z

 received in 2014-09-10, accepted in 2014-11-14,  发布年份 2014

【 摘 要 】

Objectives

To examine the evidence derived from randomized controlled clinical trials on the efficacy and safety of omalizumab compared to placebo in controlling symptoms of chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU).

Data source

The electronic databases PubMed, Medline, EMBASE, Biomed Central, The Cochrane Central Register of ControlledTrials (CENTRAL), Wiley, OVID, and HighwirePress were reviewed. The date limit was set to May 31th, but it was extended to September 30th of 2014 due to a new publication. No language restriction was used. The articles included were randomized trials controlled with placebo in individuals older than 12 years diagnosed with CIU/CSU refractory to conventional treatment, the intervention being, omalizumab at different doses, and the comparison, placebo. The primary outcome was symptom improvement according to the weekly score of urticaria severity (UAS7), the itch severity score (ISS), the weekly score of number of urticarial lesions, the dermatology life quality index, and the chronic urticaria quality of life questionnaire (CU-QoL). Databases were searched using the following Mesh or EMTREE key words including as intervention “omalizumab” or “humanized monoclonal antibody,” compared to placebo and the disease of interest “urticaria” or “angioedema”. The title, abstract and article were reviewed by two independent investigators, according to the selection criteria in each of the databases. An assessment of the quality of the articles was performed according to the bias tool from the studies of the Cochrane Collaboration. Information such as author data, date of study, number of participants, interventions, dose and frequency of administration, comparison, time of follow-up, measurements of weekly score of urticaria activity, pruritus severity score, weekly urticarial lesions, percentage of angioedema and post-treatment change were extracted. Frequency of adverse events and the ones suspected to be caused by the intervention drug were included.

Results

770 records were identified in all databases described. 720 were eliminated for failing to meet the inclusion criteria in the first review or for duplicate records. 24 articles were reviewed by abstract, 18 additional articles were further removed, leaving 6 records for inclusion. An experimental study was excluded because it wasn’t randomized. Five studies were finally included, with 1117 patients, of these 831 received a dose of omalizumab of 75 mg (183 patients, 16.38%), 150 mg (163 patients, 14.59%), 300 mg (437 patients, 39.12%) or 600 mg (21 patients, 1.8%), as a single dose, or every 4 weeks until 24 weeks maximum. The average age was 42.07 years, predominantly female gender and white ethnicity. It was observed that the use of omalizumab 300 mg lowered the weekly scores of urticarial activity in 19.9 vs. 6.9 on placebo (p <0.01), 19 vs 8.5 and 20.7 vs 8.01 in three studies, the weekly ISS (−9.2 vs. - 3.5, p <0.001, −9.8 vs −5.1 p < 0.01, −8.6 vs −4.0 and −9.4 vs −3.63 p <0.001 in four studies), and the percentage of angioedema-free days (omalizumab 95.5% vs. placebo 89.2% p <0.001, and 91.95% vs. 88.1% p <0.001 in two of the studies respectively).

Limitations

The different doses used throughout the study, time of administration and follow-up periods ranged from single dose to monthly dose for 24 weeks. Therefore no meta-analysis of the review was conducted.

Conclusions and implications of the main findings

Despite the limitations, it is considered that omalizumab 300 mg is effective in treating chronic idiopathic urticaria refractory to H1 antihistamines. Further studies are required to determine the duration of effective treatment.

Registration number of the systematic review

CRD42014010029 webcite (PROSPERO. International Prospective Register of Systematic Reviews).

【 授权许可】

   
2014 Carrillo et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Greaves MW: Chronic urticaria. N Engl J Med 1995, 332(26):1767-72.
• [2]Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M: Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004, 14(3):214-20.
• [3]Bergstrom KG: Chronic Urticaria: Omalizumab and Review of Therapeutic Options. J Drugs Dermatol 2013, 12(6):715-6.
• [4]Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S: Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007, 34(5):294-301.
• [5]Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park H-S: Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012, 4(6):357-61.
• [6]Saini SS: Chronic Spontaneous Urticaria: Etiology and Pathogenesis. Immunol Allergy Clin North Am 2014, 34(1):33-52.
• [7]Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T: Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011, 66(3):317-30.
• [8]Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Nast A, Maurer M: Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014, 69(7):e1-e29.
• [9]Francés L, Leiva-Salinas M, Silvestre JF: Omalizumab in the treatment of chronic urticaria. Actas Dermosifiliogr 2014, 105(1):45-52.
• [10]Lefévre AC, Deleuran M, Vestergaard C: A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol 2013, 25(2):242-5.
• [11]Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P: Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39(6):788-97.
• [12]Kaplan AP, Popov TA: Biologic agents and the therapy of chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol 2014, 14(4):347-53.
• [13]Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-6.
• [14]Valero A, Herdman M, Bartra J, Ferrer M, Jauregui I, Davila I, del Cuvillo A, Montoro J, Mullol J, Sastre J, Canonica GW, Baiardini I: Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol 2008, 18(6):426-32.
• [15]Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, Brzoza Z, Kasperska-Zajac A, Rogala B, Zalewska-Janowska A, Zuberbier T, Maurer M: The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009, 64(6):927-36.
• [16]Medical Search Terms Omalizumab [Available from: https://www.dropbox.com/s/8hhaisftmbxx4iy/search_strategy_%283%29%5B1%5D.pdf?dl=0]
• [17]Higgins J, Green S: Manual Cochrane de revisiones sistemáticas de intervenciones. [Available from: http://es.cochrane.org/sites/es.cochrane.org/files/uploads/Manual_Cochrane_510_reduit.pdf]
• [18]Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122(3):569-73.
• [19]Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013, 368(10):924-35.
• [20]Maurer M, Altrichter S, Bieber T, Biedermann T, Brautigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011, 128(1):202-9. e5
• [21]Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, Spector S, Maurer M: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, 128(3):567-73. e1
• [22]Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013, 132(1):101-9.
• [23]Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bulbul Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K: Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.J Invest Dermatol 2014, in press.